MEDI-GLOBE-GROUP
Medline International B.V., a leading manufacturer and distributor of healthcare supplies in Europe, and Medi-Globe Group, headquartered in Germany, announced today that Medline has entered into a definitive agreement to acquire 100% of shares of ASID BONZ GmbH from Medi-Globe Group.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220405005920/en/
ASID BONZ is a leading supplier to hospitals in Germany, offering high-quality surgery, anesthesia, ward-supply and urology products. ASID BONZ was founded in 1811 and is known worldwide for the development of the first anesthetic ether. In 2021, ASID BONZ recorded over 30mio Euros in revenues and served over 1.100 hospitals in Germany.
With similar business models and reputations for outstanding customer service, the two companies have an excellent strategic fit. Looking forward, Medline will make the ASID BONZ brand available outside of Germany to its broad European customer base. Within Germany, the ASID BONZ sales force will have access to Medline products to strengthen their partnership with customers.
“We are excited to increase our product offering and work with this award-winning organization with a renowned customer focus”, said Tripp Amdur, Medline Europe Group President. “Medline is a relatively new player in urology and anesthesia. This acquisition grows our presence in these areas of the hospital. ASID BONZ’s employees, products and service have a long-standing and trusted reputation and this combination will enable us to better meet the needs of our healthcare customers and become a more valued partner”.
Martin Lehner, CEO of Medi-Globe Group adds: “ASID BONZ is known for its unwavering commitment to its customers, providing high-quality medical products that are used to treat patients every day. We are sure that under the ownership of Medline, ASID BONZ will provide substantial avenues of growth in the future. The sale increases Medi-Globe’s focus on the core business - the development and marketing of innovative single-use products for minimally invasive diagnostic and therapeutic procedures”.
Transaction Details
We anticipate the investment will be completed in May 2022 once merger control approval has been obtained and other closing conditions have been fulfilled.
About Medline
With 27,000 employees worldwide and an especially strong presence in North America and Europe, Medline is a leading global healthcare company that manufactures and distributes quality medical and surgical supplies with superior value. Medline takes pride in serving its customers’ needs and improving healthcare around the globe, every day. Medline Europe was established in 2011. Since then, the company has expanded rapidly throughout the continent, serving customers in 27 European countries and with offices, manufacturing and distribution centers across the continent. Learn more about Medline at medline.eu
About Medi-Globe Group
The Medi-Globe Group is an innovative, fast-growing and internationally oriented medical technology group in the fields of urology, gastroenterology and pneumology. The head office is in Achenmuehle in Chiemgau, Bavaria, around 70 kilometers south of Munich. Around 670 employees work for the Medi-Globe Group, which was founded in 1990, in Germany, France, the Czech Republic, China, Brazil, the Netherlands and Austria. Customers include university clinics, specialist clinics, special medical facilities and specialists in gastroenterology, urology and pneumology in around 120 countries worldwide. The managing directors are Martin Lehner (CEO), Christian Klein (COO), Dr. Nikolaus König (CFO) and Marc Jablonowski (CTIO). More information at www.medi-globe.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005920/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom